Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/ijms23031516
Keywords
aryl hydrocarbon receptor; hyperoxia; acute lung injury; chronic obstructive pulmonary disease; and bronchopulmonary dysplasia
Funding
- NIH [R01HL139594, R01HL129794, R01ES029382, P42ES027725]
- Cancer Prevention Research Institute of Texas (CPRIT) [RP190279]
Ask authors/readers for more resources
The aryl hydrocarbon receptor (AHR) is a cytoplasmic transcription factor that plays a vital role in the development of liver and regulation of various physiological processes. This review summarizes the mechanistic role(s) and therapeutic potential of AHR in acute lung injury, chronic obstructive pulmonary disease, and bronchopulmonary dysplasia, highlighting its translational potential for managing these lung disorders.
The aryl hydrocarbon receptor (AHR) is a cytoplasmic transcription factor that is well-known for regulating xenobiotic metabolism. Studies in knockout and transgenic mice indicate that the AHR plays a vital role in the development of liver and regulation of reproductive, cardiovascular, hematopoietic, and immune homeostasis. In this focused review on lung diseases associated with acute injury and alveolar development, we reviewed and summarized the current literature on the mechanistic role(s) and therapeutic potential of the AHR in acute lung injury, chronic obstructive pulmonary disease, and bronchopulmonary dysplasia (BPD). Pre-clinical studies indicate that endogenous AHR activation is necessary to protect neonatal and adult lungs against hyperoxia- and cigarette smoke-induced injury. Our goal is to provide insight into the high translational potential of the AHR in the meaningful management of infants and adults with these lung disorders that lack curative therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available